MedTrace Logo

Digoxin Short Term Treatment Assessment Randomized Trial in AHF

NCT02544815 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2023-12-18

No results posted yet for this study

Summary

AHFS management is challenging and most of the used drugs has failed to decrease post-discharge mortality and readmission rates which represent the most important goal in AHFS.

Digoxin processes many characteristics of a beneficial drug for heart failure, however recent publications has rose concerns about its safety profile and therefore decreasing its use.

Whether digoxin is efficient and safe in short term treatment of acute heart failure is a question that should be studied.

Conditions

  • Acute Heart Failure

Interventions

DRUG

Digoxin

Digoxin 0.25 mg pills

DRUG

Placebo

Placebo pills

Sponsors & Collaborators

  • University of Monastir

    lead OTHER

Principal Investigators

  • Nouira Semir, Professor · University Hospital of Monastir

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02544815 on ClinicalTrials.gov